Progressive, advanced/metastatic well-differentiated pancreatic islet cell tumours MedDRA version: 9.1 Level: HLT Classification code 10033632 Term: Pancreatic neoplasms
Conditions
Interventions
Trade Name: SUTENT
Product Name: Sutent
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: sunitinb malate
CAS Number: 341031-54-7
Current Sponsor code: SU-0011248
Concentration unit: mg milligra
Sponsors
Pfizer Inc.
Pfizer bv CR
Pfizer bv RA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Histologically or cytologically proven diagnosis of well-differentiated pancreatic islet cell tumor (according to WHO 2000 classification.19) 2.Local, locally-advanced or metastatic disease documented as having shown progression on a scan (CT, MRI, or Octreoscan®) taken within 2 to 12 months prior to baseline compared to a previous scan (taken at any time in the past). Progression must be documented according to RECIST guidelines. Octreoscan results may be used to document progressive disease prior to study entry, but not for RECIST determination of tumor response during the study. 3.Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent. 4.Presence of at least one measurable target lesion for further evaluation according to RECIST criteria (contrast enhancing lesion with the largest diameter > 20 mm, based on CT or MRI scan done within 3 weeks before the start of treatment). 5.Adequate organ function as defined by the following: • Serum aspartate aminotransferase (AST; serum glutamate-oxalate transferase [SGOT]) and serum alanine aminotransferase (ALT; serum glutamate-pyruvate transferase [SGPT]) 3.0 g/dL • Absolute neutrophil count (ANC) >1500/uL • Platelets >100,000/uL • Hemoglobin >9.0 g/dL • Serum creatinine 3 months. 8.Age > 18 years. 9.Previous treatments with chemotherapy, loco-regional therapy (e.g., chemoembolization) or interferon are permitted providing that toxicity has resolved to =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1.Patients with poorly-differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification19). 2.Current treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational anticancer agent other than somatostatin analogues. 3.Prior treatment with any tyrosine kinase inhibitors or anti-VEGF angiogenic inhibitors. Prior treatment with non-VEGF-targeted angiogenic inhibitors is permitted. 4.Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri. 5.Treatment with potent CYP3A4 inhibitors and inducers within 7 and 12 days, respectively prior to study drug administration 6.Pre-existing thyroid abnormality of thyroid function that cannot be maintained in the normal range with medication. 7.Concomitant treatment with therapeutic doses of anticoagulants (low dose warfarin (Coumadin) up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed). 8.Unstable systemic diseases including uncontrolled hypertension (>150/100 mmHg despite optimal medical therapy) or active uncontrolled infections. 9.Current treatment on another clinical trial. 10.Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism. 11.Abnormal cardiac function with abnormal 12 lead ECG. Ongoing cardiac dysrhythmias of NCI CTC grade >2, atrial fibrillation of any grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females. 12.Symptomatic brain metastases, spinal cord compression, or new evidence of brain or leptomeningeal disease 13.Left ventricular ejection fraction (LVEF) =50% as measured by either multigated acquisition (MUGA) scan or echocardiogram (ECHO). 14.Pregnancy or breastfeeding. Female patients must be surgically sterile or postmenopausal, or must agree to use effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to starting study drug.. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the investigator or a designated associate. 15.Positive test for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness 16.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib (at a starting dose of 37.5 mg daily continuous dosing) with those treated with placebo;Primary end point(s): Progression Free Survival (PFS) defined as the time from date of randomization to first progression of disease (PD).;Secondary Objective: •To compare overall survival (OS) between sunitinib- and placebo-treated subjects •To compare objective response (OR) rate between sunitinib- and placebo-treated subjects •To compare duration of response (DR) between sunitinib- and placebo-treated subjects in subjects achieving a response. •To assess time to tumor response (TTR) for sunitinib- and placebo-treated subjects. •To assess safety and tolerability of sunitinib •Assess patient reported outcomes (PROs) | — |
Countries
Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Outcome results
None listed